My previous msg incorrectly gave the volume for the 90 DMA as 425K....oops!
It's actually only 310K, so that puts the current volume of 443K already 43 % above it, with half a day's trading remaining.
The censors are blocking my response. I'll try posting on the Investors Village board.
Short answer is yes.
I haven't received any confirmation of my registration....have you?
GSA, my comment was directed at Pezel's comment that Arun should wake up. Getting a FDA label is an ordeal and I'm sure Novadaq is awake. It just can't speak. Yet.
Just registered, and will look you up at the conference!
Buzzy, as I stated up front, there was no mention of NVDQ or it's product, just a general reference to "this new technology that made my cancer light up". I wouldn't be surprised if the vagueness of the advertisement was purposely structured that way and had U of P's lawyers review it for violations of FDA requirements. The real question is, why hasn't the FDA moved on approving this? If there is no existing "approved" method for doctors to help save lives with this type of cancer and they have now had years to review this application of existing, long standing use of Indocene Green in humans, what are their concerns? Maybe the fact that U of P went out on a limb to put this in the public is their way of putting pressure on the FDA to move.
All of this is only speculation on my part. I have no access or sources either to NVDQ's application standing or the FDA's review progress. If something is moving and they make an announcement in the next few weeks or even before the end of the year, I expect this would be an inflection point for the companies stock price.
I'm unsure if Novadaq has FDA approval for this application yet. If not, it isn't allowed to advertise off-label use.
Having attended the conference the last 3 years, I can assure you that it's time well spent.
It's a date!
What network? Time of day? Sounds like it should be part of a PR package NVDQ sends to clients.
Sentiment: Strong Buy
I'm thinking about it. I have another commitment that day but if I can get a substitute to cover for me I would like to come up to NY. If I do, the dinners on me.
Thanks for the post.
Arun: wake up! This should be blasted all over the internet, imo.
p.s. see you on investor day at Sofitel?
Without saying what the company or product was (PINPOINT?) I saw a TV commercial two days ago with a woman claiming to have a cancer that was not able to be treated because they weren't able to locate it precisely. She says in the add---At the University of Pennsylvania they have a technology that they use to make the cancer light up so the doctors can cut it out without missing any and not have to cut out good tissue. "I am now cancer free!"
If we can get more of this type of advertisement, Novadaq will take off like ISRG's Da Vinci did in the early 2000's. The same U of P had TV adds and billboards along I-95 trumpeting their Robotic Surgery capability as a leader in the Philadelphia area. It worked and soon U of P had 7 Da Vinci machines. All of the other hospitals in the Philadelphia area soon followed with their own Da Vinci's because they were loosing patients to U of P.
Anyone else see any thing like this in their areas?
I think it might be a larger deal than you think. Remember, one of the upgrades to the Pinpoint system was better optics, so that surgeons could use it as a stand-alone endoscopic system and not feel they had compromised their vision. I see this as an advancement in the same vein.
Beyond that, I'm not sure who currently makes the endoscope for Pinpoint, but allying with an state-of-the-art endoscope maker, one who isn't likely to be a future competitor, would be a good thing.
Check w/ the company. What you'll find: Anthrex approached NVDQ. Not the other way around. Anthrex is a huge player in orthopedics and has competed very successfully against SYK - they were increasingly getting questions re: fluorescence/blood flow in some procedures and in ambulatory surgery ctrs where the sell a lot of procedures are non-orthopedic - and they wanted a product answer. Not sure fluorescence is that critical to most orthopedic surgeries, but Anthrex distributes to a lot of surgical end mkts that do broader set of surgeries that just hip, shoulder, knee etc. Don't think deal is that big a deal - but kind of like the notion of SYK looking over their shoulder....
I agree - the press release is so poorly worded, you get the sense they are trying to hide something? The sense is not that Arthrex approached NVDQ and needed SPY to be competitive, but the other way around? After all the hype about kicking LifeCell to the curb and how they were in control of marketing their full product spectrum and all the related synergies, they enter a marketing deal, but provide no details on terms or have a conference call to discuss it?
Novadaq must keep up with tech advancements. To gain and maintain state-of-the-art in endoscopic systems, partnering with Arthrex may be the way to go. After looking at the Arthrex website and a video on their 4K system, I am impressed. I will reserve my yea or nay until the terms of the agreement are revealed.
I wonder if they are involved in the development of the new SPY Thoracoscope System. (See my posts on IV or search for it.)